Top Page> News> Business> Satsuma Pharmaceuticals, Inc. announced that the first patient has been enrolled in the Phase 3 clinical efficacy trial (SUMMIT™ trial) for their nasal migraine medication (development code: STS101).
Satsuma Pharmaceuticals, Inc. announced that the first patient has been enrolled in the Phase 3 clinical efficacy trial (SUMMIT™ trial) for their nasal migraine medication (development code: STS101).
By clicking on 'Cookie Settings', you can customize your cookie settings. On this website, cookies are used to personalize content and advertisements, provide social media features, and analyze traffic. Privacy Policy OK
